^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD30-targeted antibody-drug conjugate

    Related drugs:
    2d
    ECHELON-3: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL (clinicaltrials.gov)
    P3, N=239, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial primary completion date: Dec 2026 --> Jan 2026
    Trial primary completion date
    |
    Rituxan (rituximab) • lenalidomide • Adcetris (brentuximab vedotin)
    9d
    S1826: Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma (clinicaltrials.gov)
    P3, N=994, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    Opdivo (nivolumab) • doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine • Neulasta (pegfilgrastim) • ABP 206 (nivolumab biosimilar) • Neupogen (filgrastim)
    14d
    BRESELIBET: BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant (clinicaltrials.gov)
    P2, N=150, Active, not recruiting, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    cytarabine • Adcetris (brentuximab vedotin) • methylprednisolone sodium succinate
    19d
    Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients (clinicaltrials.gov)
    P2, N=58, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    Adcetris (brentuximab vedotin)
    21d
    cHL-PG01: A phase-2 academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or pembrolizumab in relapsed or refractory classical Hodgkin lymphoma (cHL) (2024-520123-83-01)
    P1/2, N=48, Active, not recruiting, Universita' Degli Studi Di Perugia | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    Keytruda (pembrolizumab) • Jakafi (ruxolitinib) • Adcetris (brentuximab vedotin)
    1m
    KEYNOTE B81: Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors (clinicaltrials.gov)
    P2, N=161, Completed, Seagen, a wholly owned subsidiary of Pfizer | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Feb 2026 | Trial primary completion date: Dec 2026 --> Feb 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • BRAF mutation • ALK mutation
    |
    Keytruda (pembrolizumab) • Adcetris (brentuximab vedotin)
    1m
    Survival Trends and Prognostic Modeling in ALK-Positive Anaplastic Large Cell Lymphoma: A Population-Based Study in the Brentuximab Vedotin Era. (PubMed, Cancer Med)
    The introduction of BV has significantly improved real-world survival in ALK+ ALCL. The RSF model enables individualized risk stratification and may support future precision treatment strategies.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    Adcetris (brentuximab vedotin)
    2ms
    BV-ALLO: Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=14, Completed, University of Cologne | Recruiting --> Completed | N=21 --> 14
    Trial completion • Enrollment change
    |
    Adcetris (brentuximab vedotin)
    2ms
    Beyond CD30: Dual-Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides. (PubMed, Adv Sci (Weinh))
    Anti-apoptotic BCL2 was upregulated in all tumor cells from nonresponsive lesions, especially in CD30- subsets. We further confirmed a potent synergy between BV and BCL2 inhibitors in tumor cell lines, indicating a promising strategy to overcome resistance in CTCL.
    Journal
    |
    CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • IFNG (Interferon, gamma) • IFNA1 (Interferon Alpha 1)
    |
    Adcetris (brentuximab vedotin)
    2ms
    ECHELON-1 : A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P3, N=1334, Completed, Takeda | Active, not recruiting --> Completed
    Trial completion
    |
    doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • bleomycin • vinblastine
    2ms
    CD25-Targeted Aptamer-Drug Conjugate for the Treatment of CD25-Expressing Hematological Malignancies. (PubMed, Pharmaceutics)
    In vivo, CD25-ApDC achieved complete tumor remission in xenograft and disseminated models with optimized dosing, showing efficacy and tolerability comparable to Brentuximab vedotin. Increasing drug-to-aptamer ratios further enhanced outcomes, supporting flexible dosing strategies. These findings highlight CD25-ApDC as a promising therapeutic modality for hematologic malignancies, offering advantages in specificity, tissue penetration, and manufacturability over conventional antibody-based therapies.
    Journal
    |
    IL2RA (Interleukin 2 receptor, alpha) • IL2 (Interleukin 2)
    |
    IL2RA expression
    |
    Adcetris (brentuximab vedotin)
    2ms
    A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India (clinicaltrials.gov)
    P4, N=124, Recruiting, Takeda | Trial completion date: Mar 2026 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine